SEC Company Response from Lite Strategy, Inc. (LITS) (CIK 0001262104) (LITS) — Nov 6, 2012
Lite Strategy, Inc. (LITS) (CIK 0001262104)
Date: Nov. 6, 2012 · CIK: 0001262104 · Accession: 0001193125-12-454413
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-184011
Letter
Correspondence
[Letterhead of MEI Pharma, Inc.]
November 6, 2012
VIA EDGAR TRANSMISSION
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Jeffrey Riedler, Assistant Director
Johnny Gharib
Bryan J. Pitko
Re:
MEI Pharma, Inc.
Registration Statement on Form S-3 (Registration No. 333-184011)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, MEI Pharma, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (Registration No. 333-184011), so that the Registration Statement may become effective at 4:30 p.m. (Washington, DC time) on November 8, 2012, or as soon as practicable thereafter.
In connection with this request, the Company acknowledges that:
•
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
MEI PHARMA, INC.
By:
/s/ Thomas M. Zech
Name:
Thomas M. Zech
Title:
Chief Financial Officer
Show Raw Text
CORRESP
1
filename1.htm
Correspondence
[Letterhead of MEI Pharma, Inc.]
November 6, 2012
VIA EDGAR TRANSMISSION
Securities and Exchange Commission
100 F
Street, N.E.
Washington, D.C. 20549
Attention:
Jeffrey Riedler, Assistant Director
Johnny Gharib
Bryan J. Pitko
Re:
MEI Pharma, Inc.
Registration Statement on Form S-3 (Registration No. 333-184011)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, MEI Pharma, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3
(Registration No. 333-184011), so that the Registration Statement may become effective at 4:30 p.m. (Washington, DC time) on November 8, 2012, or as soon as practicable thereafter.
In connection with this request, the Company acknowledges that:
•
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing
effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from
its full responsibility for adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person
under the federal securities laws of the United States.
MEI PHARMA, INC.
By:
/s/ Thomas M. Zech
Name:
Thomas M. Zech
Title:
Chief Financial Officer